Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Assets Average (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Assets Average readings, the most recent being $99.1 million for Q4 2025.

  • On a quarterly basis, Assets Average rose 25.09% to $99.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $99.1 million, a 25.09% increase, with the full-year FY2025 number at $79.3 million, down 28.42% from a year prior.
  • Assets Average hit $99.1 million in Q4 2025 for Aligos Therapeutics, down from $122.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $249.9 million in Q1 2021 to a low of $79.3 million in Q4 2024.
  • Median Assets Average over the past 5 years was $137.0 million (2023), compared with a mean of $154.1 million.
  • Biggest five-year swings in Assets Average: tumbled 44.61% in 2023 and later increased 25.09% in 2025.
  • Aligos Therapeutics' Assets Average stood at $249.2 million in 2021, then crashed by 37.65% to $155.4 million in 2022, then dropped by 23.61% to $118.7 million in 2023, then tumbled by 33.22% to $79.3 million in 2024, then rose by 25.09% to $99.1 million in 2025.
  • The last three reported values for Assets Average were $99.1 million (Q4 2025), $122.2 million (Q3 2025), and $142.7 million (Q2 2025) per Business Quant data.